Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

DNA risk report may nudge people to shield from sun

NCT ID NCT03509467

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving people personalized information about their genetic risk for melanoma could encourage them to protect themselves from the sun. Over 2,000 adults received either standard sun safety tips or tailored advice based on their DNA. Researchers then tracked sun exposure, sunscreen use, and sunburns to see if the personalized message made a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized DNA risk information
What this could lead to
If it works, this approach could help people adopt better sun protection habits and lower their risk of skin cancer.
What could go wrong
This is a completed behavioral study, not a treatment trial. Results rely on self-reported behaviors, which may not reflect actual sun exposure or long-term change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2,054 people

The number who actually took part.

Started

Aug 2015

Finished

Feb 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: CRITERIA FOR: NON-HISPANIC WHITE POPULATION * Investigators will recruit participants from the Family Medicine and General Internal Medicine clinics of the Morsani Center at the University of South Florida. * White, non-Hispanic patients who self-report a low phenotypic risk profile for development of melanoma and are able to read and speak English fluently. * 18 years of age or older * Capable of giving informed consent * Potential participants will be screened for eligibility based on responses to questions about skin phenotypes, early detection behaviors and past history of melanoma. * After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm. CRITERIA FOR: HISPANIC POPULATION * Investigators will recruit participants living in Tampa Bay and Puerto Rico as part of the U54 Ponce Health Sciences University-Moffitt Cancer Center (PHSU-MCC) Partnership. In Tampa Bay, participants will be recruited from the Family Medicine and General Internal Medicine clinics of the Morsani Center at the University of South Florida, and from the Suncoast Community Health Centers. * Patients who self-report as Hispanics and are able to read and speak either Spanish or English fluently. * 18 years of age or older * Capable of giving informed consent * Potential participants will be screened for eligibility based on responses to early detection behaviors and past history of melanoma. * After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm. Exclusion Criteria: CRITERIA FOR: NON-HISPANIC WHITE POPULATION * Have had a skin examination within the past year. * Do not meet race/ethnicity criteria for their group * White, non-Hispanic group - participants reporting sun-sensitive phenotypes * A personal history of melanoma CRITERIA FOR: HISPANIC POPULATION * Have had a skin examination within the past year. * Do not meet ethnicity criteria for their group * White, non-Hispanic group - participants reporting sun-sensitive phenotypes * Participants with a personal history of melanoma and/or more personal history of more than on squamous cell cancer (SCC) and/or Basal Cell Cancer (BCC)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal cell cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

  • Ponce School of Medicine

    Ponce, 00716, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.